Login to Your Account

Other News To Note

Wednesday, November 16, 2011
• Avraham Pharmaceuticals Ltd., of Jerusalem, raised $3 million from Yissum Research Development Co. Ltd., the technology transfer arm of the Hebrew University of Jerusalem, and other investors. The funding will be used for an ongoing Phase II trial of ladostigil in Alzheimer's disease and a planned study of the drug in mild cognitive impairment. Ladostigil is a cholinesterase and brain-selective monoamine oxidase inhibitor.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription